Tag: renal denervation
CMS grants transitional pass-through payment for Medtronic’s Symplicity Spyral and Recor’s...
The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Medtronic's Symplicity Spyral renal denervation (RDN) catheter and Recor...
TCT 2024: Two-year SPYRAL HTN-ON MED show “consistent” effect of renal...
Medtronic has announced new, long-term data from the SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity...
Renal denervation gains class IIb recommendation in ESC guidelines
Latest guidelines from the European Society of Cardiology (ESC) on the management of blood pressure and hypertension include a recommendation for the use of...
Money-maker or meritable: Is renal denervation out of retirement?
In a paper published in the July 2024 issue of the Journal of Hypertension, Andrew Sharp (University Hospital of Wales and Cardiff University, Cardiff,...
Interventional News Issue 95—August 2024 Edition
Interventional News 95 Highlights:
Findings from a post-hoc analysis of Lutonix arteriovenous (AV) global registry data
Interview with Philip Dombrowski (Cape Cod Hospital, Hyannis,...
First patients treated in US GPS study of Paradise renal denervation...
The first patients in the USA have been treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS), a real-world study...
Study of TIVUS renal denervation system for hypertension treatment completes enrolment
The REDUCED-1 study, a US Food and Drug Administration (FDA) investigational device exemption (IDE)-approved pilot study of the treatment of hypertension with the...
Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial
A new trial of endovascular ultrasound-based renal denervation technology has found that it reduced blood pressure in hypertensive patients at two months. The RADIANCE...
Results on ReCor Medical’s Paradise ultrasound renal denervation system published in...
ReCor Medical and its parent company, Otsuka Medical Devices, recently announced that primary endpoint results from the RADIANCE II pivotal trial were published in...
ESC and EAPCI publish renal denervation consensus statement
Renal denervation represents another treatment option in patients with uncontrolled resistant hypertension and may be used in selected patients deemed intolerant to antihypertensive drugs.
These...
Interventional News’ top 10 most popular stories in 2022
Interventional News covered a whole range of the specialty's news during 2022, but readers' attention was most piqued by acquisitions (Boston Scientific's of Obsidio...
Interventional News’ top 10 most popular stories of November 2022
Interventional News’ most popular stories last month included news of a US Food and Drug Administration pre-market approval submission of an ultrasound renal denervation...
Otsuka Medical Devices and ReCor Medical submit pre-market approval of Paradise...
Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the pre-market approval (PMA) application to the US Food and...
ReCor Medical announces consistent reduction of blood pressure in pooled analysis...
ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...
SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other...
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The late-breaking data were presented at the...
TCT 2022 hears “important data” from renal denervation trials
Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September, Boston, USA), “confirm that ultrasound...
SoniVie announces successful procedure with Tivus system on first patient enrolled...
SoniVie today announced that on 30 May this year the first patient was treated with its renal artery denervation Tivus therapeutic intravascular ultrasound technology, as...
SoniVie receives FDA IDE approval for pilot study to treat hypertension...
SoniVie recently announced that on 5 May 2022 the US Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its REDUCED1...
TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal...
Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasound renal denervation to a sham procedure for treatment-resistant hypertension, demonstrate the additional effects...
Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study
Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during...
ESH position paper highlights renal denervation as a third option for...
The European Society of Hypertension (ESH) has presented an updated position paper on renal denervation (RDN) in a pre-ESH congress satellite symposium (10–11 September,...
Multi-organ denervation to combat cardiometabolic disease: A novel concept put to...
Following a successful proof-of-concept study, Gerard S Goh and Markus P Schlaich have embarked upon a first-in-human study to explore the safety and efficacy...
EuroPCR 2021: Late-breaking data demonstrate long-term benefits of Medtronic radiofrequency renal...
Medtronic today announced new clinical data from the Global SYMPLICITY registry (GSR) indicating that renal denervation with the Medtronic Symplicity renal denervation system was...
PCR e-Course 2020: Sham patients from RADIANCE-HTN SOLO who crossed over...
Patients who crossed over from the sham control arm of the RADIANCE-HTN SOLO trial to the renal denervation arm after 12 months of elevated...
Virtual ACC: Renal denervation bests sham control to safely lower blood...
Three months after undergoing renal denervation, patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared...
UK consensus statement on renal denervation “strongly encourages” clinicians to tell...
In a new consensus statement, the Joint UK Societies (JUKS)—which includes the British Society of Interventional Radiology—say that the evidence for renal denervation is “insufficient”...
TARGET BP I trial enrols its first patient
The first patient has been randomised in the TARGET BP I trial at the Piedmont Heart Institute in Atlanta, USA, to investigate the use...
EuroPCR 2019: Renal denervation linked to reduction in subclinical atrial fibrillation
Data presented at EuroPCR today indicates that renal denervation with the Symplicity system (Medtronic) is associated with a reduction in subclinical atrial fibrillation in...
The resurgence of renal denervation
More than ever before, arterial hypertension represents one of the greatest health threats and challenges for both patients and treating physicians. With the new...
US FDA approve new study of Medtronic’s Spyral renal denervation system
The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with hypertension who...
Otsuka Holdings, Otsuka Medical Devices and ReCor Medical to merge
Otsuka Holdings, Otsuka Medical Devices, and ReCor Medical have signed a merger agreement pursuant to which Otsuka Holdings will acquire the remaining shares in...
FDA approves RADIANCE-II study of Paradise ultrasound denervation system
The RADIANCE-II study of the Paradise Ultrasound Denervation System (ReCor Medical) for the treatment of hypertension has been approved by the US Food &...
New renal denervation data show significant blood pressure reduction in patients...
Late-breaking SPYRAL HTN-ON MED study at EuroPCR indicates renal denervation lowers blood pressure in hypertensive patients in presence of blood pressure medication.
Medtronic has announced...
From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal...
It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study...
ESC 2017: MobiusHD implant shown to reduce resistant hypertension
The European results of the first-in-human trial of Vascular Dynamics’ MobiusHD implant indicate that the device is associated with a reduction in 24-hour ambulatory...
